Ipsen and EpiVax collaborate on next generation botulinium neurotoxin

27 October 2015

French drugmaker Ipsen (Euronext: IPN) and US company EpiVax have completed a collaborative project on next generation botulinium neurotoxin (BoNT) and targeted secretion inhibitor (TSI) therapeutics.

EpiVax will move Ipsen’s program forward and continue potential product development for clinical use in neuromuscular health and aesthetic treatments. EpiVax is to present the results of the research program so far at the IBRCC 2015 conference.

Claude Bertrand, executive vice president of R&D and chief scientific officer of Ipsen, said: “Ipsen is pleased to have had a partnership with the US company EpiVax. This work is part of Ipsen’s commitment to apply modern protein engineering and recombinant protein expression to enable development of novel and improved botulinum neurotoxin products for increased therapeutic utility and patient care”.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK